Gene therapy may be a safe and effective single-dose treatment for soft bone disease

A preclinical study led by scientists at Sanford Burnham Prebys has established that AAV8-TNAP-D10–a gene therapy that replaces a key enzyme found in bone–may be a safe and effective single-dose treatment for hypophosphatasia (HPP).